WallStreetZenWallStreetZen

NASDAQ: CGEM
Cullinan Oncology Inc Stock

$10.53+0.37 (+3.64%)
Updated Jun 2, 2023
CGEM Price
$10.53
Fair Value Price
$3,358.56
Market Cap
$414.47M
52 Week Low
$7.78
52 Week High
$15.89
P/E
7.92x
P/B
0.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$65.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$156M
Beta
1.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CGEM Overview

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGEM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CGEM ($10.53) is undervalued by 99.69% relative to our estimate of its Fair Value price of $3,358.56 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CGEM ($10.53) is significantly undervalued by 99.69% relative to our estimate of its Fair Value price of $3,358.56 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CGEM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more CGEM due diligence checks available for Premium users.

Be the first to know about important CGEM news, forecast changes, insider trades & much more!

CGEM News

Valuation

CGEM fair value

Fair Value of CGEM stock based on Discounted Cash Flow (DCF)
Price
$10.53
Fair Value
$3,358.56
Undervalued by
99.69%
CGEM ($10.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGEM ($10.53) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

CGEM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
7.92x
Industry
11.51x
Market
52.69x
CGEM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CGEM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

CGEM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.85x
Industry
5.2x
CGEM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CGEM's financial health

Profit margin

Revenue
$0.0
Net Income
-$58.0M
Profit Margin
0%
CGEM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$515.0M
Liabilities
$29.3M
Debt to equity
0.06
CGEM's short-term assets ($399.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGEM's short-term assets ($399.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGEM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$51.0M
Investing
$15.2M
Financing
$1.8M
CGEM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CGEM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CGEM$414.47M+3.64%7.92x0.85x
AVTE$416.48M-0.48%-7.17x3.68x
VERA$412.07M+4.02%-2.70x2.61x
OTLK$411.95M-1.53%-6.42x39.28x
KOD$410.47M+23.46%-1.33x1.05x

Cullinan Oncology Stock FAQ

What is Cullinan Oncology's quote symbol?

(NASDAQ: CGEM) Cullinan Oncology trades on the NASDAQ under the ticker symbol CGEM. Cullinan Oncology stock quotes can also be displayed as NASDAQ: CGEM.

If you're new to stock investing, here's how to buy Cullinan Oncology stock.

What is the 52 week high and low for Cullinan Oncology (NASDAQ: CGEM)?

(NASDAQ: CGEM) Cullinan Oncology's 52-week high was $15.89, and its 52-week low was $7.78. It is currently -33.73% from its 52-week high and 35.31% from its 52-week low.

How much is Cullinan Oncology stock worth today?

(NASDAQ: CGEM) Cullinan Oncology currently has 39,360,916 outstanding shares. With Cullinan Oncology stock trading at $10.53 per share, the total value of Cullinan Oncology stock (market capitalization) is $414.47M.

Cullinan Oncology stock was originally listed at a price of $29.91 in Jan 8, 2021. If you had invested in Cullinan Oncology stock at $29.91, your return over the last 2 years would have been -64.79%, for an annualized return of -40.67% (not including any dividends or dividend reinvestments).

How much is Cullinan Oncology's stock price per share?

(NASDAQ: CGEM) Cullinan Oncology stock price per share is $10.53 today (as of Jun 2, 2023).

What is Cullinan Oncology's Market Cap?

(NASDAQ: CGEM) Cullinan Oncology's market cap is $414.47M, as of Jun 5, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cullinan Oncology's market cap is calculated by multiplying CGEM's current stock price of $10.53 by CGEM's total outstanding shares of 39,360,916.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.